임상시험 시장 : 시장 분석 및 예측 - 유형별, 제품별, 서비스별, 기술별, 컴포넌트별, 용도별, 전개별, 최종 사용자별, 모드별, 단계별(-2035년)

The global Clinical Trials Market is projected to grow from $59.9 billion in 2025 to $112.3 billion by 2035, at a compound annual growth rate (CAGR) of 6.5%. The clinical trials market is driven by the growing pipeline of drug candidates, increasing pharmaceutical and biotechnology R&D activities, and rising demand for efficient drug development processes. According to the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP), more than 500,000 clinical trials have been registered globally, highlighting the continued expansion of clinical research across oncology, rare diseases, vaccines, and advanced therapies. The increasing adoption of decentralized clinical trials, digital technologies, and real-world data analytics is improving trial efficiency, patient recruitment, and participant engagement.

The Type segment of the Clinical Trials Market includes interventional trials, observational trials, expanded access trials, and others. Interventional trials represent a major segment due to their critical role in evaluating the safety, efficacy, and therapeutic outcomes of new drugs, biologics, vaccines, and medical devices through controlled clinical studies. The increasing development of innovative therapies, rising prevalence of chronic diseases, and growing investments in drug discovery are driving the demand for interventional trials globally. Observational trials are also gaining importance as they enable real-world evidence generation, long-term safety monitoring, and assessment of treatment outcomes in diverse patient populations. Expanded access trials are witnessing growth due to increasing demand for early access to investigational therapies for patients with serious or life-threatening conditions, particularly in oncology and rare disease research.

The Stage segment of the Clinical Trials Market includes Phase I, Phase II, Phase III, Phase IV, and others. Phase III trials account for a significant share due to their extensive role in confirming the efficacy, safety, and optimal dosage of therapies before regulatory approval. The increasing number of drug candidates entering late-stage development, rising pharmaceutical R&D expenditure, and expansion of clinical research activities are supporting the growth of Phase III trials. Phase II trials are also expanding rapidly as they provide essential data on therapeutic effectiveness and dosage optimization during early clinical development. Meanwhile, Phase IV trials are gaining momentum due to the growing emphasis on post-marketing surveillance, real-world evidence collection, and continuous safety evaluation of approved treatments. Phase I trials are supported by increasing innovation in precision medicine, cell and gene therapies, and novel biologics requiring early safety and tolerability assessments.

Geographical Overview

North America held the largest share of the global clinical trials market in 2025, supported by its well-established pharmaceutical and biotechnology ecosystem, advanced healthcare infrastructure, and strong regulatory framework. The region benefits from significant investments in research and development by both public agencies and private organizations, enabling a high volume of Phase IIV clinical studies across therapeutic areas. The widespread presence of leading contract research organizations (CROs), academic medical centers, and experienced investigators further strengthens trial execution capabilities. In addition, increasing adoption of decentralized and virtual clinical trial technologies, combined with favorable regulatory initiatives and high patient awareness, continues to reinforce North America's leadership in the global clinical trials market.

The Asia Pacific clinical trials market is expected to register the highest growth due to expanding pharmaceutical manufacturing, improving healthcare infrastructure, and increasing government support for biomedical research. Countries such as China, India, South Korea, Japan, and Australia are attracting global sponsors through large and diverse patient populations, cost-efficient trial operations, and ongoing regulatory reforms that accelerate study approvals. Rising investments in biotechnology, precision medicine, and digital health are further boosting regional demand for clinical research. Moreover, multinational pharmaceutical companies are increasingly shifting clinical development activities to Asia Pacific to reduce costs and improve patient recruitment, positioning the region as a key global hub for future clinical trial expansion.

Key Trends and Drivers

Digital Transformation in Clinical Trials:

The clinical trials market is undergoing a digital transformation, driven by the adoption of advanced technologies such as artificial intelligence (AI), machine learning, and blockchain. These technologies enhance data management, patient recruitment, and trial monitoring, leading to more efficient and cost-effective trials. AI and machine learning algorithms are particularly useful in identifying suitable candidates and predicting outcomes, while blockchain ensures data integrity and security. This digital shift is expected to streamline operations and accelerate the drug development process.

Growing Pipeline of Biopharmaceuticals and Precision Medicines:

The expanding pipeline of biologics, cell and gene therapies, precision medicines, and targeted therapeutics is a major driver of the Clinical Trials Market. Increasing investments by pharmaceutical and biotechnology companies in innovative drug development have significantly raised the number of investigational therapies entering clinical evaluation. The growing prevalence of chronic diseases, cancer, neurological disorders, and rare diseases has further intensified demand for well-designed clinical studies to establish safety and efficacy. Additionally, regulatory agencies are supporting faster development pathways for innovative therapies, encouraging sponsors to initiate more clinical trials and expand global research activities, thereby driving sustained market growth.

Research Scope

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Services
• 2.4 Key Market Highlights by Technology
• 2.5 Key Market Highlights by Application
• 2.6 Key Market Highlights by End User
• 2.7 Key Market Highlights by Stage
• 2.8 Key Market Highlights by Mode
• 2.9 Key Market Highlights by Component
• 2.10 Key Market Highlights by Deployment

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Interventional Trials
  • 4.1.2 Observational Trials
  • 4.1.3 Expanded Access Trials
  • 4.1.4 Others
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Drugs
  • 4.2.2 Biologics
  • 4.2.3 Medical Devices
  • 4.2.4 Vaccines
  • 4.2.5 Others
• 4.3 Market Size & Forecast by Services (2020-2035)
  • 4.3.1 Site Identification
  • 4.3.2 Patient Recruitment
  • 4.3.3 Data Management
  • 4.3.4 Regulatory Services
  • 4.3.5 Clinical Monitoring
  • 4.3.6 Laboratory Services
  • 4.3.7 Others
• 4.4 Market Size & Forecast by Technology (2020-2035)
  • 4.4.1 Wearable Technology
  • 4.4.2 Artificial Intelligence
  • 4.4.3 Blockchain
  • 4.4.4 Cloud Computing
  • 4.4.5 Big Data Analytics
  • 4.4.6 Others
• 4.5 Market Size & Forecast by Application (2020-2035)
  • 4.5.1 Oncology
  • 4.5.2 Cardiology
  • 4.5.3 Neurology
  • 4.5.4 Infectious Diseases
  • 4.5.5 Gastroenterology
  • 4.5.6 Endocrinology
  • 4.5.7 Others
• 4.6 Market Size & Forecast by End User (2020-2035)
  • 4.6.1 Pharmaceutical Companies
  • 4.6.2 Biotechnology Companies
  • 4.6.3 Medical Device Manufacturers
  • 4.6.4 Contract Research Organizations
  • 4.6.5 Academic Institutes
  • 4.6.6 Others
• 4.7 Market Size & Forecast by Stage (2020-2035)
  • 4.7.1 Phase I
  • 4.7.2 Phase II
  • 4.7.3 Phase III
  • 4.7.4 Phase IV
  • 4.7.5 Others
• 4.8 Market Size & Forecast by Mode (2020-2035)
  • 4.8.1 In-House
  • 4.8.2 Outsourced
  • 4.8.3 Others
• 4.9 Market Size & Forecast by Component (2020-2035)
  • 4.9.1 Software
  • 4.9.2 Hardware
  • 4.9.3 Services
  • 4.9.4 Others
• 4.10 Market Size & Forecast by Deployment (2020-2035)
  • 4.10.1 On-Premise
  • 4.10.2 Cloud-Based
  • 4.10.3 Others

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Services
    • 5.2.1.4 Technology
    • 5.2.1.5 Application
    • 5.2.1.6 End User
    • 5.2.1.7 Stage
    • 5.2.1.8 Mode
    • 5.2.1.9 Component
    • 5.2.1.10 Deployment
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Services
    • 5.2.2.4 Technology
    • 5.2.2.5 Application
    • 5.2.2.6 End User
    • 5.2.2.7 Stage
    • 5.2.2.8 Mode
    • 5.2.2.9 Component
    • 5.2.2.10 Deployment
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Services
    • 5.2.3.4 Technology
    • 5.2.3.5 Application
    • 5.2.3.6 End User
    • 5.2.3.7 Stage
    • 5.2.3.8 Mode
    • 5.2.3.9 Component
    • 5.2.3.10 Deployment
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Services
    • 5.3.1.4 Technology
    • 5.3.1.5 Application
    • 5.3.1.6 End User
    • 5.3.1.7 Stage
    • 5.3.1.8 Mode
    • 5.3.1.9 Component
    • 5.3.1.10 Deployment
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Services
    • 5.3.2.4 Technology
    • 5.3.2.5 Application
    • 5.3.2.6 End User
    • 5.3.2.7 Stage
    • 5.3.2.8 Mode
    • 5.3.2.9 Component
    • 5.3.2.10 Deployment
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Services
    • 5.3.3.4 Technology
    • 5.3.3.5 Application
    • 5.3.3.6 End User
    • 5.3.3.7 Stage
    • 5.3.3.8 Mode
    • 5.3.3.9 Component
    • 5.3.3.10 Deployment
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Services
    • 5.4.1.4 Technology
    • 5.4.1.5 Application
    • 5.4.1.6 End User
    • 5.4.1.7 Stage
    • 5.4.1.8 Mode
    • 5.4.1.9 Component
    • 5.4.1.10 Deployment
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Services
    • 5.4.2.4 Technology
    • 5.4.2.5 Application
    • 5.4.2.6 End User
    • 5.4.2.7 Stage
    • 5.4.2.8 Mode
    • 5.4.2.9 Component
    • 5.4.2.10 Deployment
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Services
    • 5.4.3.4 Technology
    • 5.4.3.5 Application
    • 5.4.3.6 End User
    • 5.4.3.7 Stage
    • 5.4.3.8 Mode
    • 5.4.3.9 Component
    • 5.4.3.10 Deployment
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Services
    • 5.4.4.4 Technology
    • 5.4.4.5 Application
    • 5.4.4.6 End User
    • 5.4.4.7 Stage
    • 5.4.4.8 Mode
    • 5.4.4.9 Component
    • 5.4.4.10 Deployment
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Services
    • 5.4.5.4 Technology
    • 5.4.5.5 Application
    • 5.4.5.6 End User
    • 5.4.5.7 Stage
    • 5.4.5.8 Mode
    • 5.4.5.9 Component
    • 5.4.5.10 Deployment
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Services
    • 5.4.6.4 Technology
    • 5.4.6.5 Application
    • 5.4.6.6 End User
    • 5.4.6.7 Stage
    • 5.4.6.8 Mode
    • 5.4.6.9 Component
    • 5.4.6.10 Deployment
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Services
    • 5.4.7.4 Technology
    • 5.4.7.5 Application
    • 5.4.7.6 End User
    • 5.4.7.7 Stage
    • 5.4.7.8 Mode
    • 5.4.7.9 Component
    • 5.4.7.10 Deployment
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Services
    • 5.5.1.4 Technology
    • 5.5.1.5 Application
    • 5.5.1.6 End User
    • 5.5.1.7 Stage
    • 5.5.1.8 Mode
    • 5.5.1.9 Component
    • 5.5.1.10 Deployment
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Services
    • 5.5.2.4 Technology
    • 5.5.2.5 Application
    • 5.5.2.6 End User
    • 5.5.2.7 Stage
    • 5.5.2.8 Mode
    • 5.5.2.9 Component
    • 5.5.2.10 Deployment
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Services
    • 5.5.3.4 Technology
    • 5.5.3.5 Application
    • 5.5.3.6 End User
    • 5.5.3.7 Stage
    • 5.5.3.8 Mode
    • 5.5.3.9 Component
    • 5.5.3.10 Deployment
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Services
    • 5.5.4.4 Technology
    • 5.5.4.5 Application
    • 5.5.4.6 End User
    • 5.5.4.7 Stage
    • 5.5.4.8 Mode
    • 5.5.4.9 Component
    • 5.5.4.10 Deployment
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Services
    • 5.5.5.4 Technology
    • 5.5.5.5 Application
    • 5.5.5.6 End User
    • 5.5.5.7 Stage
    • 5.5.5.8 Mode
    • 5.5.5.9 Component
    • 5.5.5.10 Deployment
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Services
    • 5.5.6.4 Technology
    • 5.5.6.5 Application
    • 5.5.6.6 End User
    • 5.5.6.7 Stage
    • 5.5.6.8 Mode
    • 5.5.6.9 Component
    • 5.5.6.10 Deployment
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Services
    • 5.6.1.4 Technology
    • 5.6.1.5 Application
    • 5.6.1.6 End User
    • 5.6.1.7 Stage
    • 5.6.1.8 Mode
    • 5.6.1.9 Component
    • 5.6.1.10 Deployment
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Services
    • 5.6.2.4 Technology
    • 5.6.2.5 Application
    • 5.6.2.6 End User
    • 5.6.2.7 Stage
    • 5.6.2.8 Mode
    • 5.6.2.9 Component
    • 5.6.2.10 Deployment
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Services
    • 5.6.3.4 Technology
    • 5.6.3.5 Application
    • 5.6.3.6 End User
    • 5.6.3.7 Stage
    • 5.6.3.8 Mode
    • 5.6.3.9 Component
    • 5.6.3.10 Deployment
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Services
    • 5.6.4.4 Technology
    • 5.6.4.5 Application
    • 5.6.4.6 End User
    • 5.6.4.7 Stage
    • 5.6.4.8 Mode
    • 5.6.4.9 Component
    • 5.6.4.10 Deployment
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Services
    • 5.6.5.4 Technology
    • 5.6.5.5 Application
    • 5.6.5.6 End User
    • 5.6.5.7 Stage
    • 5.6.5.8 Mode
    • 5.6.5.9 Component
    • 5.6.5.10 Deployment

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 IQVIA
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Labcorp
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 ICON
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Parexel
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Syneos Health
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 PPD
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Charles River Laboratories
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Medpace
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Covance
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 PRA Health Sciences
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Wuxi AppTec
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 KCR
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Pharm-Olam
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Worldwide Clinical Trials
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Clinipace
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Novotech
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Tigermed
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Celerion
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Frontage Laboratories
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 BioClinica
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us